Similar companies
Income Statement (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Operating expense | 25M | 15.9% |
| Net Income | -23M | 15.2% |
| EBITDA | -24M | 15.2% |
Balance Sheet (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Total Assets | 141M | 10.5% |
| Total Liabilities | 13M | 12.6% |
| Total Equity | 128M | 12.4% |
| Shares Outstanding | 48M | 0.3% |
Cash Flow (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Cash from operations | -11M | 81.5% |
| Cash from financing | 90,000 | 90.2% |
EPS
Financial Highlights for Cassava Sciences in Q1 '25
Operating Expenses for this period were 25M, showing a -15.9% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -23M, showing a 15.2% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -24M, showing a 15.2% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
The company's performance remained stable this quarter with no significant positive or negative changes in the key financial metrics.
